Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by toinv261on Feb 14, 2018 9:05am

147 Views

Post# 27556389

RE:RE:RE:RE:RE:RE:RE:HOPE THIS DOES NOT HAPPEN TO RVX

GV, thanks for the background and new understanding. This gives me a new appreciation of Don's capabilities on the fund raising side and also on value protection side. This gives me new hope for Don's next move. He seems to have some sort of geographic licensing strategy happening.

I guess my current frustration is that we know more about apabetalone both from RVX as well as independent academic researchers. All of the findings are positive and new evidence continues to come in. We are close to the sample size estimation and very close to top lines. So I like most others are frustrated by the share price.

However, in my opinion, it is a fabulous time to buy.

Thanks again GV.
Toinv

Bullboard Posts

Who, why, and what of the great "Crypto Surge"